Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial

Treatment with metformin glycinate reduces SARS-CoV-2 viral load: An in vitro model and randomized, double-blind, Phase IIb clinical trial

The health crisis caused by the new coronavirus SARS-CoV-2 highlights the need to identify new treatment strategies for this viral infection. During the past year, over 400 coronavirus disease (COVID-19) treatment patents have been registered; nevertheless, the presence of new virus variants has tri...

Full description

Bibliographic Details
Main Authors: Claudia Ventura-López, Karla Cervantes-Luevano, Janet S. Aguirre-Sánchez, Juan C. Flores-Caballero, Carolina Alvarez-Delgado, Johanna Bernaldez-Sarabia, Noemí Sánchez-Campos, Laura A. Lugo-Sánchez, Ileana C. Rodríguez-Vázquez, Jose G. Sander-Padilla, Yulia Romero-Antonio, María M. Arguedas-Núñez, Jorge González-Canudas, Alexei F. Licea-Navarro
Format: Article
Language:English
Published: Elsevier 2022-08-01
Series:Biomedicine & Pharmacotherapy
Subjects:
SARS-CoV-2 viral load
COVID-19 treatment
Metformin glycinate
SARS-CoV-2 variants
Online Access:http://www.sciencedirect.com/science/article/pii/S0753332222006126

Internet

http://www.sciencedirect.com/science/article/pii/S0753332222006126

Similar Items